Iron Carboxymaltose
Iron Carboxymaltose is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
IV Iron-induced Hypophosphatemia After RYGB
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure
Clinical Trials (9)
EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
IV Iron-induced Hypophosphatemia After RYGB
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation
Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency
Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9